Sulé-Suso Josep, Watson Nick A, van Pittius Daniel G, Jegannathen Apurna
Cancer Centre, Royal Stoke University Hospital, University Hospitals of North Midlands (UHNM), Stoke on Trent, UK.
Institute for Science and Technology in Medicine, Guy Hilton Research Centre, Keele University, Stoke on Trent, UK.
SAGE Open Med Case Rep. 2019 Feb 21;7:2050313X19832160. doi: 10.1177/2050313X19832160. eCollection 2019.
In spite of new drugs, lung cancer is associated with a very poor prognosis. While targeted therapies are improving outcomes, it is not uncommon for many patients to have only a partial response, and relapse during follow-up. Thus, new drugs or re-evaluation of existing therapies used to treat other non-malignant diseases (drug repurposing) are still needed. While this research both and is being carried out, it is important to be attentive to patients where the disease responds to treatments not considered standard in clinical practice. We report here a patient with adenocarcinoma of the lung who, after declining chemotherapy and radiotherapy, presented with tumour response following self-administration of cannabidiol, a non-psychoactive compound present in . Prior work has shown that cannabidiol may have anti-neoplastic properties and enhance the immune response to cancer. The data presented here indicate that cannabidiol might have led to a striking response in a patient with lung cancer.
尽管有了新药,但肺癌的预后仍然很差。虽然靶向治疗正在改善治疗效果,但许多患者仅出现部分缓解且在随访期间复发的情况并不少见。因此,仍需要新药或重新评估用于治疗其他非恶性疾病的现有疗法(药物重新利用)。在进行这项研究的同时,关注那些疾病对临床实践中未被视为标准治疗有反应的患者非常重要。我们在此报告一名肺癌腺癌患者,在拒绝化疗和放疗后,自行服用大麻二酚(一种存在于大麻中的非精神活性化合物)后出现肿瘤反应。先前的研究表明,大麻二酚可能具有抗肿瘤特性并增强对癌症的免疫反应。此处呈现的数据表明,大麻二酚可能使一名肺癌患者产生了显著反应。